Evaluation of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis

被引：0
|
作者：
Schumacher, W. A. [1 ]
Bostwick, J. S. [1 ]
Stewart, A. B. [1 ]
Xin, B. [1 ]
Wong, P. C. [1 ]
机构：
[1] Bristol Myers Squibb, Thrombosis Res, Pennington, NJ USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-TH-202
引用
收藏
页码：1001 / 1001
页数：1
相关论文
共 50 条
  • [31] Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban
    Morishima, Yoshiyuki
    Honda, Yuko
    Kamisato, Chikako
    PHARMACOLOGY, 2019, 103 (1-2) : 17 - 22
  • [32] Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits
    Donglu Zhang
    Kan He
    Nirmala Raghavan
    Lifei Wang
    Earl J. Crain
    Bing He
    Baomin Xin
    Joseph M. Luettgen
    Pancras C. Wong
    Journal of Thrombosis and Thrombolysis, 2010, 29 : 70 - 80
  • [33] Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits
    Zhang, Donglu
    He, Kan
    Raghavan, Nirmala
    Wang, Lifei
    Crain, Earl J.
    He, Bing
    Xin, Baomin
    Luettgen, Joseph M.
    Wong, Pancras C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 29 (01) : 70 - 80
  • [34] Antithrombotic properties of DU-176b, a novel, potent and orally active direct factor Xa inhibitor in rat models of arterial and venous thrombosis: Comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor.
    Fukuda, T
    Matsumoto, C
    Honda, Y
    Sugiyama, N
    Morishima, Y
    Shibano, T
    BLOOD, 2004, 104 (11) : 513A - 513A
  • [35] The direct factor Xa inhibitor rivaroxaban
    Verma, Abhishek K.
    Brighton, Timothy A.
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (07) : 379 - 383
  • [36] EFFECT OF BODY WEIGHT ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Upreti, Vijay V.
    Wang, Jessie
    Barrett, Yuchen
    Boyd, Rebecca
    Bui, Anh
    Li, Tong
    LaCreta, Frank P.
    Frost, Charles E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1060 - 1060
  • [37] DIRECT FACTOR Xa INHIBITOR APIXABAN PREVENTS ENDOTHELIAL ACTIVATION AND DAMAGE ASSOCIATED WITH CHRONIC KIDNEY DISEASE
    Cases, Aleix
    Vera, Manel
    Palomo, Marta
    Torramade, Sergi
    Escolar, Gines
    Diaz-Ricart, Maribel
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [38] In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor.
    Luettgen, Joseph M.
    Bozarth, Tracy A.
    Bozarth, Jeffrey M.
    Barbera, Frank A.
    Lam, Patrick Y.
    Quan, Mimi L.
    Pinto, Donald J.
    Wexler, Ruth R.
    Rendina, Alan R.
    Knabb, Robert M.
    BLOOD, 2006, 108 (11) : 112B - 112B
  • [39] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    Buller, H.
    Deitchman, D.
    Prins, M.
    Segers, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) : 1313 - 1318
  • [40] Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
    Kan He
    Joseph M. Luettgen
    Donglu Zhang
    Bing He
    James E. Grace
    Baomin Xin
    Donald J. P. Pinto
    Pancras C. Wong
    Robert M. Knabb
    Patrick Y. S. Lam
    Ruth R. Wexler
    Scott J. Grossman
    European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36 : 129 - 139
12345